LTFS
BTAI icon

Ladenburg Thalmann Financial Services’s BioXcel Therapeutics BTAI Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$15K Hold
63
– – ﹤0.01% 4278
2019
Q3 		$7K Hold
63
– – ﹤0.01% 4527
2019
Q2 		$11K Buy
63
+32
+103% +$5.42K ﹤0.01% 4376
2019
Q1 		$5K Buy
+31
New +$3.82K ﹤0.01% 4637

Other funds holding BTAI

AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ladenburg Thalmann Financial Services's BTAI Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its BioXcel Therapeutics (BTAI) position steady in Q4 2019 at 63 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #4278.

Ladenburg Thalmann Financial Services first reported a position in BTAI in Q1 2019 and has held it in 4 quarters since. 43 funds tracked by Wall St. Rank hold BTAI as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 63 shares of BioXcel Therapeutics worth $15K as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its BioXcel Therapeutics share count unchanged in Q4 2019.
  • BioXcel Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4278 holding.
  • Ladenburg Thalmann Financial Services first reported a position in BioXcel Therapeutics in Q1 2019 and has held it in 4 quarters since.
  • 43 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.